Prognostic factors for the development of lower respiratory tract infection after influenza virus infection in allogeneic hematopoietic stem cell transplantation recipients: A Kanto Study Group for Cell Therapy multicenter analysis

Harada, Kaito; Onizuka, Makoto; Mori, Takehiko; Shimizu, Hiroaki; Seo, Sachiko; Aotsuka, Nobuyuki; Takeda, Yusuke; Sekiya, Noritaka; Kusuda, Machiko; Fujiwara, Shin-Ichiro; Shiraiwa, Sawako; Shono, Katsuhiro; Shingai, Naoki; Kanamori, Heiwa; Momoki, Mamiko; Takada, Satoru; Mukae, Junichi; Masuda, Saeko; Mitani, Kinuko; Sakaida, Emiko; Tomikawa, Tatsuki; Takahashi, Satoshi; Usuki, Kensuke; Kanda, Yoshinobu

doi:10.1016/j.ijid.2023.03.045

Cited by 2 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among recipients of allo-HCT in the pre-COVID-19 pandemic era, hospital-acquired FLU infection was highly associated with all-cause mortality (odds ratio, OR, 4.9 [95% CI, 3.6–6.5]), respiratory failure requiring mechanical ventilation (OR, 5.5 [95% CI, 4.1–7.3]), development of acute kidney injury (OR, 2.70 [95% CI, 2.1–3.5]), and septic shock (OR, 2.7 [95% CI, 1.8–4.1]) [43]. Among adult allo-HCT recipients with FLU infection, age at least 50 years (HR, 2.2 [95% CI, 1.0–4.6]) and moderate to severe chronic GVHD (HR, 2.3 [95% CI, 1.1–4.6]) were associated with progression to LRTI [44 ▪ ]. Importantly, neuraminidase inhibitor treatment within 48 h of disease onset was highly associated with lowered risk of progression (HR, 0.17 [95% CI, 0.06–0.46]) [44 ▪ ].…”

Section: Risk Factors For Severity In Influenza Virusmentioning

confidence: 99%

“…Among adult allo-HCT recipients with FLU infection, age at least 50 years (HR, 2.2 [95% CI, 1.0–4.6]) and moderate to severe chronic GVHD (HR, 2.3 [95% CI, 1.1–4.6]) were associated with progression to LRTI [44 ▪ ]. Importantly, neuraminidase inhibitor treatment within 48 h of disease onset was highly associated with lowered risk of progression (HR, 0.17 [95% CI, 0.06–0.46]) [44 ▪ ]. FLU vaccination is one of the most effective preventive strategies.…”

Section: Risk Factors For Severity In Influenza Virusmentioning

confidence: 99%

See 1 more Smart Citation

Risk factors for severity in seasonal respiratory viral infections and how they guide management in hematopoietic cell transplant recipients

Matsui,

Ogimi

2023

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

Purpose of review Seasonal respiratory virus infections (RVIs) often progress to severe diseases in hematopoietic cell transplant (HCT) recipients. This review summarizes the current evidence on risk factors for the severity of RVIs in this high-risk population and provides clinical management. Recent findings The likelihood of the respiratory viral disease progression depends on the immune status of the host and the type of virus. Conventional host factors, such as the immunodeficiency scoring index and the severe immunodeficiency criteria, have been utilized to estimate the risk of progression to severe disease, including mortality. Recent reports have suggested nonconventional risk factors, such as hyperglycemia, hypoalbuminemia, prior use of antibiotics with broad anaerobic activity, posttransplant cyclophosphamide, and pulmonary impairment after RVIs. Identifying novel and modifiable risk factors is important with the advances of novel therapeutic and preventive interventions for RVIs. Summary Validation of recently identified risk factors for severe RVIs in HCT recipients is required. The development of innovative interventions along with appropriate risk stratification is critical to improve outcomes in this vulnerable population.

show abstract

Section: Risk Factors For Severity In Influenza Virusmentioning

confidence: 99%

Section: Risk Factors For Severity In Influenza Virusmentioning

confidence: 99%

Risk factors for severity in seasonal respiratory viral infections and how they guide management in hematopoietic cell transplant recipients

Matsui,

Ogimi

2023

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

show abstract

Respiratory virus infections after allogeneic stem cell transplantation: Current understanding, knowledge gaps, and recent advances

Piñana,

Pérez,

Chorão

et al. 2023

Transplant Infectious Dis

View full text Add to dashboard Cite

Before the COVID‐19 pandemic, common community‐acquired seasonal respiratory viruses (CARVs) were a significant threat to the health and well‐being of allogeneic hematopoietic cell transplant (allo‐HCT) recipients, often resulting in severe illness and even death. The pandemic has further highlighted the significant risk that immunosuppressed patients, including allo‐HCT recipients, face when infected with SARS‐CoV‐2. As preventive transmission measures are relaxed and CARVs circulate again among the community, including in allo‐HSCT recipients, it is crucial to understand the current state of knowledge, gaps, and recent advances regarding CARV infection in allo‐HCT recipients. Urgent research is needed to identify seasonal respiratory viruses as potential drivers for future pandemics.

show abstract

Prognostic factors for the development of lower respiratory tract infection after influenza virus infection in allogeneic hematopoietic stem cell transplantation recipients: A Kanto Study Group for Cell Therapy multicenter analysis

Cited by 2 publications

References 30 publications

Risk factors for severity in seasonal respiratory viral infections and how they guide management in hematopoietic cell transplant recipients

Risk factors for severity in seasonal respiratory viral infections and how they guide management in hematopoietic cell transplant recipients

Respiratory virus infections after allogeneic stem cell transplantation: Current understanding, knowledge gaps, and recent advances

Contact Info

Product

Resources

About